Interventional device developer Guidant has completed enrollment in Spirit First, a clinical trial evaluating the Indianapolis-based firm's second drug-eluting stent system for the treatment of coronary artery disease.
The trial compares an everolimus-eluting stent system utilizing Guidant's cobalt chromium Multi-Link Vision Coronary Stent System platform with a durable polymer drug carrier, versus an uncoated Multi-Link Vision Coronary Stent System control, the company said.
The Spirit First study enrolled a total of 60 patients at multiple sites in the Netherlands, Denmark, and Germany. The primary endpoint of the study is in-stent late loss (a measurement of the re-narrowing of the vessel caused by tissue re-growth inside the stent) at six months, according to Guidant.
By AuntMinnie.com staff writersApril 1, 2004
Related Reading
Guidant, Johnson & Johnson ink stent deal, February 27, 2004
Boston Scientific, Guidant settle litigation, February 23, 2004
Guidant ups quarterly dividend, sets repurchasing plan, February 18, 2004
Guidant acquires AFx, February 10, 2004
Guidant keeps up growth in 2003, January 29, 2004
Copyright © 2004 AuntMinnie.com
